Single Ascending Dose Study With 5-MeO-DMT in Healthy Subjects

The study will evaluate safety, tolerability and PK profile of 5-MeO-DMT in healthy subjects.

Topic Healthy Subjects
Compound 5-MeO-DMT
Country United Kingdom
Visit trial
Status Recruiting
Results Published
Start date 15 September 2021
End date 16 March 2022
Chance of happening 100%
Design Blinded
Type Interventional
Generation Second
Participants 42
Sex All
Age 18- 99
Therapy No

Trial Details

A Double-Blind, Randomized, Phase 1, First-in-Human, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of Intranasal 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in Healthy Subjects

NCT Number NCT05032833

Sponsors & Collaborators

King's College London
The Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King's College London is one of Europe's top centres for mental health and related neurosciences research.

Beckley Psytech
Beckley Psytech is working on getting 5-MeO-DMT to market as the first of a variety of psychedelic medicines.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.